NCT02942017 - A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C) | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

September 17, 2017

Study Completion Date

October 11, 2017

Conditions

Postpartum Depression

Interventions

DRUG

Placebo

Intravenous infusion of matching placebo for SAGE-547.

DRUG

SAGE-547 90 μg/kg/h

Intravenous infusion of SAGE-547

Trial Locations (32)

11004

Sage Investigational Site, Glen Oaks

19104

Sage Investigational Site, Philadelphia

27514

Sage Investigational Site, Chapel Hill

27612

Sage Investigational Site, Raleigh

28211

Sage Investigational Site, Charlotte

30331

Sage Investigational Site, Atlanta

32502

Sage Investigational Site, Pensacola

32607

Sage Investigational Site, Gainesville

32807

Sage Investigational Site, Orlando

33027

Sage Investigational Site, Miramar

33147

Sage Investigational Site, Miami

33782

Sage Investigational Site, Pinellas Park

39232

Sage Investigational Site, Flowood

41017

Sage Investigational Site, Edgewood

42303

Sage Investigational Site, Owensboro

43210

Sage Investigational Site, Columbus

45417

Sage Investigational Site, Dayton

60169

Sage Investigational Site, Hoffman Estates

67226

Sage Investigational Site, Wichita

72758

Sage Investigational Site, Rogers

75080

Sage Investigational Site, Richardson

77030

Sage Investigational Site, Houston

77058

Sage Investigational Site, Houston

77521

Sage Investigational Site, Baytown

78229

Sage Investigational Site, San Antonio

84058

Sage Investigational Site, Orem

85226

Sage Investigational Site, Chandler

91945

Sage Investigational Site, Lemon Grove

92868

Sage Investigational Site, Orange

93003

Sage Investigational Site, Ventura

02114

Sage Investigational Site, Boston

08053

Sage Investigational Site, Marlton

All Listed Sponsors

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY